TABLE 1.
Patient characteristics
| HCVi | SVR | Wilcoxon paired test (HCVi vs. SVR) | |
|---|---|---|---|
| Number of subjects (n) | 29 | 23 | 22 |
| Age; median (IQR) | 59 (54.5–62) | 58 (48–67) | — |
| Gender; Males, n (%) | 18 (62.1) | 14 (61) | — |
| Race; n (%) | |||
| Caucasian | 19 (65.5) | 15 (65.2) | — |
| African American | 5 (17.2) | 5 (21.7) | — |
| Asian | 2 (6.8) | 1 (4.3) | — |
| Hispanic | 3 (10.3) | 2 (8.7) | — |
| HCV genotype; n (%) | |||
| 1a | 10 (34.5) | — | — |
| 1b | 8 (27.5) | — | — |
| 2a/c | 1 (3.4) | — | — |
| 2b | 5 (17.2) | — | — |
| 3a | 4 (13.8) | — | — |
| 4 | 1 (3.4) | — | — |
| Histological and laboratory parameters, median (IQR) | |||
| log HCV RNA (IU/mL) | 6.4 (5.75–6.88) | Undetectable | — |
| Ishak fibrosis score | 4 (2–6) | 3 (0–6) | 0.2483 |
| HAI inflammatory score | 8 (7–10) | 3 (2–3) | <0.0001 |
| Direct portal pressures (mm Hg) | 19 (12–25) | 19 (12–22) | 0.9488 |
| Laboratory parameters, median (IQR) | |||
| ALT (IU/L) | 85 (46.0–145.5) | 21 (17–29) | <0.0001 |
| AST (IU/L) | 72 (34.5–109.5) | 24 (21–28) | <0.0001 |
| ALP (IU/L) | 81 (73.0–108.5) | 76 (63–106) | 0.1172 |
| GGT (IU/L) | 113 (35.5–169.0) | 33 (20–43) | 0.0001 |
| Albumin (g/dL) | 4.1 (4.0–4.4) | 4.3 (4.1–4.5) | 0.0532 |
| Total bilirubin (mg/dL) | 0.6 (0.5–0.8) | 0.4 (0.3–0.6) | 0.0020 |
| Platelet count (×109 /L) | 165 (116.0–201.5) | 170.5 (140.8–195.8) | 0.3331 |
| PT-INR | 1.07 (0.99–1.13) | 1.09 (1.01–1.17) | 0.0083 |
| BMI (kg/m2) | 27.3 (24.4–31.4) | 27.7 (23.8–31.1) | 0.2313 |
Note: Twenty-nine patients infected with HCV were assessed at the initial time point, that is, HCVi cohort. Twenty-three patients completed evaluation at the second time point, 6 months after sustained virologic response, that is, SVR cohort. Of these, 22 patients were included in the paired analysis between the 2 time points, 2-sided Wilcoxon matched-pairs signed rank test.
Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; GGT, gamma-glutamyl transferase; HAI, hepatic activity index; HCVi, HCVi, patients infected with HCV; PT-INR, prothrombin time-international normalized ratio; SVR, sustained virologic response.